HRIPT vs Clinical vs Consumer Testing: Substantiating K-Beauty Claims
Quick Answer
Match the test to the exact words on your label. An HRIPT backs safety wording such as “dermatologist tested,” an instrumental clinical study backs “clinically proven” results, and a consumer perception study backs only what users say they noticed. Korean test institutes run all three, but the protocol must be written for US claims and run on your final formula.
The words on your front label are promises, and in the US you need the proof in hand before you print them. “Dermatologist tested,” “hypoallergenic,” and “clinically proven to hydrate” look alike on a carton. They rest on three very different human studies.
Claim substantiation refers to the evidence a brand holds before a claim runs. Leave it late and it surfaces at the worst moment: a retail buyer or a competitor asks for the data, and the ODM’s test report covers a different formula version or a different claim. My rule for founders is simple: write the claims list before the formula brief, then buy the tests that prove those exact words.
Key Takeaways
- HRIPT data supports safety wording about irritation and sensitization. It never supports efficacy.
- “Clinically proven” needs measured, instrument-based results. A questionnaire cannot carry it.
- Consumer perception studies support perception wording only, such as users saying skin felt softer.
- FDA has no federal definition of “hypoallergenic,” so your test design becomes your definition.
- Korea already requires claim substantiation at home, but export-only products can follow US rules instead. Confirm which report covers your exact formula.
Why Does Your Claim Wording Decide Which Test You Need?
Claim wording decides the test because each human study answers one narrow question. An HRIPT asks whether a formula irritates or sensitizes skin. A clinical study asks whether a measurable skin property changed. A perception study asks what users believe they experienced.
US law puts the burden on the brand. The FTC expects a reasonable basis for any objective ad claim before it runs, and when an ad says “tests prove” or “clinically shown,” the brand must hold at least that level of proof (FTC Policy Statement on Advertising Substantiation).
FDA adds a second filter. The claim itself can turn a cosmetic into a drug. FDA lists promises such as increasing or decreasing melanin production or regenerating cells as drug claims, whatever the product is called (FDA: Is It a Cosmetic, a Drug, or Both?). So the order matters. Decide what you want to say, remove anything that crosses into drug territory, then buy the test that proves what is left.
HRIPT, Clinical, and Consumer Tests Side by Side
The three tests differ in what they measure, how long they run, and which label words they can carry. Use this table as a first filter, then confirm the protocol with the test institute before you sign anything.
| Test | What it measures | Label wording it can support | Wording it cannot support |
|---|---|---|---|
| HRIPT (human repeat insult patch test) | Irritation and allergic sensitization under repeated, occluded patches | “Dermatologist tested” (when a dermatologist supervises), “hypoallergenic” (as you define it), “tested on sensitive skin” (when the panel includes it) | Any efficacy claim; “will not cause reactions” |
| Instrumental clinical study | Measured change in hydration, elasticity, or water loss against baseline or a control | “Clinically shown to boost skin hydration,” tied to the endpoint and time point measured | Endpoints nobody measured; drug claims such as “regenerates cells” |
| Consumer perception study | What users report on a structured questionnaire after home use | Perception wording, such as “most users said their skin felt softer” | “Clinically proven” or any claim about measured results |
| Specialty in-use tests | Pore-clogging potential; eye-area tolerance | “Non-comedogenic,” “ophthalmologist tested” | General safety or efficacy outside that scope |
Sun protection sits outside this table: in the US, an SPF claim makes a product an OTC drug with its own testing rules.
What Does an HRIPT Prove, and What Doesn’t It?
An HRIPT (human repeat insult patch test) is a safety study that shows whether a formula irritates skin or triggers allergic sensitization when it is applied again and again under a patch. It proves tolerance on the panel tested. It does not prove the product works, and it does not promise that no user will ever react.
The common design runs about six weeks. Patches go on the same site three times a week for three weeks, the panel rests for roughly two weeks, and then a challenge patch goes on a fresh site with skin reads over the following days (example HRIPT protocol, ClinicalTrials.gov; Politano and Api, Regulatory Toxicology and Pharmacology, 2008).
Two claims depend on it:
- “Hypoallergenic.” FDA states there are no federal standards or definitions for the term, and brands do not submit hypoallergenicity data to FDA (FDA Cosmetics Safety Q&A). Nobody pre-approves your claim, so your test design becomes the definition a buyer or a competitor will examine.
- “Dermatologist tested.” The word has to be literal. Ask for the supervising dermatologist’s name and credentials in the report, not only an institute stamp.
If you plan to say “suitable for sensitive skin,” the panel should include participants screened for sensitive skin, and the report should state how they were screened.
Only Instrumental Clinical Studies Can Carry “Clinically Proven”
A “clinically proven” claim needs a clinical study that measured the promised result with instruments or trained expert grading. A questionnaire cannot carry it, because the claim itself tells shoppers that clinical proof exists.
NAD, the advertising industry’s self-regulatory reviewer, applies this logic in beauty cases. It recommended that Solawave discontinue several efficacy claims for its skincare wand after finding the supporting 30-day in-home study too weak, citing no washout period and participants’ concurrent use of other anti-aging products (BBB National Programs decision). In another 2025 case, NAD found certain peptide efficacy claims for SBLA Beauty’s eye wand supported but recommended dropping comparisons to a surgical eyelift (Happi, NAD 2025 roundup). The data backed the ingredient claim, not the bigger promise.
Clinical studies measure one or a few endpoints. Common ones are skin hydration, elasticity, and transepidermal water loss. Your claim can name only what was measured, over the period that was measured. If the study ran four weeks, “instant results” is off the table.
Keep the endpoint cosmetic. “Visibly smoother-looking skin” describes appearance. “Regenerates cells” is on FDA’s list of drug-type claims, no matter how strong the data looks.
“I’m Liz, I run altameet from Manhattan, NYC. The cheapest claims test is the one you design once: final formula, final claims list, and a protocol written for US wording. If you want a quick gut-check on whether your claims match your data, I’ll give you 15 minutes free.”
When Is a Consumer Perception Study Enough?
A consumer perception study is a structured survey of people who used the product, and it is enough when the claim reports what users felt or saw, and says so. “Most users said their skin felt softer after two weeks” is perception wording. “Softens skin in two weeks” is an efficacy claim and needs measured data.
Perception studies fit sensory and experience claims well: texture, absorption, and how skin feels the next morning.
Two design details decide whether the results hold up. First, the sample and the questions must fit the purpose of the survey; Korean rules state exactly that for survey-based substantiation (Korea Ministry of Government Legislation, easylaw). Second, disclose the method on pack or in the ad: a user survey, how many people took part, and how long they used the product.
Korea’s Claim-Substantiation Rules Give Founders a Head Start
Korea already requires cosmetic businesses to prove factual label and ad claims. Under Article 14 of the Cosmetics Act, MFDS can demand substantiation data, and a company that fails to submit it within 15 days can be ordered to stop the ad (easylaw.go.kr).
Accepted evidence includes human application test data, non-human test data, or survey data of an equal or higher level, produced with scientific and objective methods that are widely accepted. The detailed MFDS rule adds that human application tests are run at universities or specialized research institutes, under a relevant medical specialist or an investigator with at least five years in the testing field (MFDS rule on cosmetic claim substantiation, law.go.kr).
Korea has an established network of cosmetic test institutes that run these studies. Dermapro runs safety, efficacy, and sensory studies, and the Korea Institute of Dermatological Sciences lists HRIPT among its safety tests.
One catch matters for US founders. Korea’s substantiation rules do not apply to products made only for export, which can follow the importing country’s rules instead. A domestic version’s “tested” badge therefore says little about your US formula or your US wording. Ask which exact formula code each report covers.
How Should You Commission Claim Testing Through a Korean ODM?
Commission testing in six steps, in this order, so every report matches your final formula and your final wording.
- Write the claims list. Put every sentence you want on the carton, product pages, and ads into one document.
- Screen for drug claims. Cut or rewrite anything that promises to change the structure or function of skin, using FDA’s intended-use test.
- Map each claim to a test. One HRIPT can support several safety claims. Efficacy claims usually need one measured endpoint each.
- Brief the ODM and the institute together. Add claims and tests to your Korean ODM product brief, and ask for an English protocol, ethics review details, panel criteria, and the supervising dermatologist’s name.
- Test the final formula. Any change after testing, even a preservative swap, needs a documented decision on whether the old data still applies.
- File every report twice. Keep one copy in your claim-support file and one in the safety substantiation records that MoCRA requires the responsible person to maintain (FDA: MoCRA).
Three mistakes create avoidable rework. Founders reuse an ingredient supplier’s study as proof for a finished product. They test a lab sample, then change the fragrance. They print a survey result as if it were a clinical measurement.
Claims also have to sit correctly on the pack. Pair this checklist with the US labeling guide for Korean skincare and the FDA and MoCRA requirements for Korean skincare. Still shaping the brand itself? Start with the step-by-step guide to starting a K-beauty skincare brand.
Claims Testing Checklist
Get the claim-to-test checklist as a free PDF, straight to your inbox.
Frequently Asked Questions
Does FDA approve claims like “dermatologist tested” before launch?
No. FDA does not pre-approve cosmetic claims, and it has no federal definition for “hypoallergenic.” The brand must make sure each claim is truthful and backed by evidence before launch, and regulators or competitors can challenge it later.
Can I reuse my ingredient supplier’s clinical data for product claims?
Only for carefully worded ingredient claims, and only when the study conditions match your use. Supplier data describes the ingredient at the tested level, in the tested base. A finished-product claim such as “this serum hydrates” needs a study on your finished formula.
How long does an HRIPT take?
A standard HRIPT takes about six weeks from the first patch to the final challenge read: about three weeks of induction, about two weeks of rest, and a challenge week. Add time for panel recruitment, ethics review, and report translation.
Do I need new tests if my Korean ODM already tested the formula for Korea?
Often, yes. Korean domestic reports can cover a different formula version or Korean claim wording, and export-only products are not bound by Korean substantiation rules. Ask for the formula code and claim list each report covers, then fill the gaps with a US-focused protocol.
By Liz Song, K-beauty sourcing consultant.
